

58. (New Claim) The method of claim 26, wherein said vector is a delayed expression vector.
59. (New Claim) The method of claim 26, wherein said vector contains regulatory sequences.

### **REMARKS**

Applicant has elected, the species "a non-genetic therapeutic agent", the species "a metallic stent", and the species "nitric oxide synthase", for prosecution in the present application.

Additionally, new claims 52-59 have been added. Support for these claims can be found throughout the specification but particularly in originally filed claims 8, 9, 14, 30, 32, 33, 37, and 39. Accordingly, claims : 1, 3, 10-12, 17-20, 23-27, 34-36, 38, 42-44, 47, 48, 50-59 are pending. No new matter has been added by the foregoing amendments.

### **CONCLUSION**


If any extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 11-0600. If there the Examiner has any questions or concerns, he is invited to call the undersigned.

Respectfully submitted,

KENYON & KENYON

Oct. 4, 2002  
Date

1500 K Street, NW - Suite 700  
Washington, DC 20005  
telephone: 202/220-4322  
facsimile: 202/220-4201

  
Thomas A. Haag, Ph.D.  
Reg. No. 47,621